1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow Practice Guidelines as Topic: new trials by email Literature Review of Practice Guidelines as Topic trials Research Report on Practice Guidelines as Topic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) Best Practice, Tocilizumab - Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Emory University | 2020-04-07 | 2020-06-18 |
COVID-19 (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Kidney Failure, Chronic (1) · Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1) · Stroke (1)
Emory University (1)
United States (1)
Ajay K Nooka (1)
P30CA138292 (1)